Recently, therapeutic options for patients with recurrent and/or metastatic squamous cell carcinomas (RMHNSCC) were transformed by the FDA‐approval of immune checkpoint inhibitors (ICI) targeting programmed cell death protein 1 (PD‐1). The gene discussed is PDCD1; the disease is metastatic squamous cell carcinoma.